Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus TESTOPEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus TESTOPEL.
DELATESTRYL vs TESTOPEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Testosterone is an androgen receptor agonist; it binds to and activates androgen receptors, leading to changes in gene expression that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects.
50 to 200 mg intramuscularly every 2 to 4 weeks.
Subcutaneous implantation: 150-450 mg every 3-6 months. Individualize based on serum testosterone levels and clinical response.
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Terminal half-life: 8-10 days; due to prolonged release from subcutaneous depot, effective half-life extends to 2-3 weeks.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Renal: ~90% as glucuronide and sulfate conjugates, ~10% unchanged; fecal: ~6% via biliary elimination.
Category C
Category C
Androgen
Androgen